Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
The purpose of this study was to investigate the efficacy and safety of antidepressant augmentation with agomelatine in the treatment of patients with depression who did not demonstrate satisfying response to selective serotonin…
- Trial name
- NCT04589143
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Central South University
Postpartum Hemorrhage, Postpartum Women
Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage
The objective of this cross-sectional study is to assess the prevalence of depression at 2 months, 6 months, and 1 year postpartum in women who had an immediate postpartum hemorrhage (immediate PPH defined as blood loss ≥ 500 mL…
- Conditions
- Postpartum Hemorrhage, Postpartum Women, Postpartum Depression, Postpartum Stress
- Trial name
- PSYCHE (NCT03120208)
- Testing
- • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11., The GAD-7 with a discrimination threshold ≥10., • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
- Where
- France
- Volunteers
- 1,298 people
- Sponsor
- University Hospital, Clermont-Ferrand
Major Depressive Disorder
Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD), Withdrawn
The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD).
- Trial name
- NCT03769350
- Testing
- Smartphone-delivered CBT for MDD
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Alcohol Use Disorder
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Recent reports have shown that alcohol misuse is a particularly serious problem among the 18 to 25 year old age group. Previous medication trials with SSRI antidepressants among young adults with co-occurring depressive…
- Trial name
- YAAD-P (NCT02646449)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Opioid Use Disorder, Depressive Disorder
Ketamine for OUD and Comorbid Depression (OUDCD)
Methadone is a first-line, evidence-based treatment for opioid use disorder (OUD). Unfortunately, retention and adherence in methadone treatment is a major challenge.
- Trial name
- NCT05051449
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Behavior, Depressive Disorder
Can Computational Measures of Task Performance Predict Psychiatric Symptoms and Changes in Symptom Severity Across Time
This study investigates the computational mechanisms associated with psychiatric disease dimensions. The study will characterize the relationship between computational parameter estimates of task performance and psychiatric…
- Conditions
- Behavior, Depressive Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- CABxtime (NCT06705179)
- Testing
- Behavioral task performance
- Where
- 2 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- California Institute of Technology
Treatment Resistant Depression
Rapid Acting Transcranial Magnetic Stimulation
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- NCT04739969
- Testing
- Active TBS-DLPFC
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Depressive Disorder, Treatment-Resistant
Personalized rTMS for Resistant Depression
The investigators hypothesize that personalizing the rTMS targets using functional MRI will increase its efficacy. The most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously.
- Trial name
- NCT02863380
- Testing
- Functional magnetic resonance imaging used to individualize rTMS protocol, Individualized rTMS (transcranial magnetic stimulation), Classical rTMS (transcranial magnetic stimulation)
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Strasbourg, France
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Anxiety Disorders, Depressive Disorders
Behavioral and Affective Skills in Coping (BASIC) Open Trial
The overall objective of the project is to develop and assess the feasibility of a brief, practice-friendly approach to psychotherapy for children, entitled Behavioral and Affective Skills in Coping (BASIC) and designed for use…
- Conditions
- Anxiety Disorders, Depressive Disorders, Disruptive Behavior Disorders
- Trial name
- BASIC (NCT01463241)
- Testing
- Behavioral and Affective Skills in Coping (BASIC)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Judge Baker Children's Center
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Autism, Major Depressive Disorder (MDD)
Investigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography
The goal of this observational study is to investigate the brain physiological responses in depression and autism. The main questions aim to answer are: 1.
- Trial name
- NCT06821646
- Testing
- Positron Emission Tomography (PET), transcranial magnetic stimulation and electroencephalography(TMS-EEG)
- Where
- Taiwan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Depressive Disorder, Pregnancy
EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy
The purpose of this study is to assess the effectiveness of the EnBrace HR prenatal supplement in preventing depression in women with a history of depression who have decided to stop taking antidepressants during their pregnancy…
- Trial name
- NCT02676882
- Testing
- EnBrace HR
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease, Idiopathic, Freezing of Gait
Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease
The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate/severe FOG…
- Conditions
- Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise Specified
- Trial name
- NCT06805266
- Testing
- Vortioxetine (tablet)
- Volunteers
- 40 people
- Sponsor
- Marianna Amboni
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Depression - Major Depressive Disorder, Depression Bipolar
Digital Phenotypes for Predicting Depression
This longitudinal study aims to identify and validate digital phenotypes that can predict recurrence of major depressive episodes using passively collected, real-time sensing data from smartphones and wearable devices.
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Bipolar Disorder (BD), Mood Disorders
- Trial name
- NCT07151846
- Where
- South Korea
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Treatment-resistant Depression (TRD)
Personalized DBS Targeting for Treating Depression
The goal of this clinical trial is to optimize the target brain areas for deep brain stimulation (DBS) for depression based on personalized brain imaging and stereo-electroencephalography（SEEG), to administer long-term DBS…
- Trial name
- NCT06784388
- Testing
- Deep Brain Stimulation(DBS), Esketamine
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development